Company: SHPH
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001493152-25-002253
Chunk: 165

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-15
Form: S-1
Chunk 165
---
 |
| Income taxes                                                                            |     | $                 |          - |   |     | $    |          - |   |
| Supplemental non-cash financing activities:                                             |     |                   |            |   |     |      |            |   |
| Common stock issued for settlement of debt                                              |     | $                 |  1,947,294 |   |     | $    |  2,697,849 |   |
| Warrants issued for financing fees, net of issuance fees of $0 and $8,727, respectively |     | $                 |          - |   |     | $    |     90,816 |   |
| Initial recognition of right of use asset and liability                                 |     | $                 |          - |   |     | $    |    365,556 |   |

<div align='center'>The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</div>

| F-5 |

<div align='center'>Shuttle Pharmaceuticals Holdings, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

September 30, 2024</div>

Note 1 – Organization and Liquidity

Organization and Line of Business

Shuttle Pharmaceuticals Holdings, Inc. (“we,” “us,” “our,” or the “Company”) was originally formed as Shuttle Pharmaceuticals, LLC in the State of Maryland on December 18, 2012. On August 12, 2016, the Company filed articles of conversion with the State of Maryland to convert from an LLC to a C corporation, at which time the Company changed its name to Shuttle Pharmaceuticals, Inc. (“Shuttle”). In connection with the conversion the Company issued 5,625,000shares of common stock in exchange for 100% of the outstanding membership interests in Shuttle prior to conversion. On June 4, 2018, Shuttle completed a reverse merger with Shuttle Pharmaceuticals Holdings, Inc. (then known as Shuttle Pharma Acquisition Corp, Inc.), a Delaware corporation, pursuant to which Shuttle, our operating entity, became a wholly-owned subsidiary of the Company. All share numbers referenced herein reflect a 1-for-8 reverse split of our common stock on a post-split basis, which was effective as of August 13, 2024 (see Note 2).

The Company’s primary purpose is to develop and commercialize unique drugs for the sensitization of cancers and protection of normal tissues, with the goal of improving outcomes for cancer patients receiving radiation therapy.